Clinical Trials Logo

Urothelial Carcinoma Bladder clinical trials

View clinical trials related to Urothelial Carcinoma Bladder.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04688931 Terminated - Bladder Cancer Clinical Trials

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

ATLAS
Start date: February 19, 2021
Phase: Phase 3
Study type: Interventional

This global, randomized, controlled, open-label Phase 3 study was designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

NCT ID: NCT03606174 Terminated - Clinical trials for Urothelial Carcinoma

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Start date: September 11, 2018
Phase: Phase 2
Study type: Interventional

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.